knowledge -WSS

knowledge

author：hotspot 2025-09-29 06:21:26 Page View：72599

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The blockbuster weight loss and diabetes drug sold by Eli Lilly also appears to improve fatty liver disease, according to early clinical trial data the pharmaceutical company released Tuesday.

Eli Lilly reported during its fourth-quarter earnings call that tirzepatide, which is sold commercially as Mounjaro or Zepbound, succeeded in a Phase 2 test as a treatment for the liver disease MASH. Around 74% of adults in the trial taking the drug were free of MASH after 52 weeks, compared to approximately 13% of the placebo group.

MASH, formerly known as NASH, is a liver disease characterized by excess fat and inflammation. The chronic inflammation can also lead to liver scarring, or fibrosis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Study: People of West African ancestry at greater risk of cardiac amyloidosis
Next article： How to save PrEP access — and even expand it

knowledge

Activists slam private health insurers over coverage restrictions

ProtestorsoutsideAmerica'sHealthInsurancePlansheadquarters.CourtesyPeople'sActionWASHINGTON—Hun

What nurses really want: sufficient staffing for patient care

AdobePizza.Coloringbooks.Goodybags.Theycouldbeactivitiesata5-year-old’sbirthdayparty.Butthey’renot:T

How to save PrEP access — and even expand it

UndertheAffordableCareAct,healthinsurersarerequiredtocoverallcostsassociatedwithpreventivecare—inclu

Making AI in medicine accessible to smaller, and rural hospitals

NorthCountryHealthCareInKingman,Ariz.,awindsweptcityof35,000attheeasternedgeoftheMojavedesert,datasc

knowledge

focus

knowledge

Making AI in medicine accessible to smaller, and rural hospitals